EurekaMag.com logo
+ Site Statistics
References:
54,215,046
Abstracts:
30,230,908
PMIDs:
28,215,208
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Evaluation of in vitro resistance in patients with onychomycosis who fail antifungal therapy



Evaluation of in vitro resistance in patients with onychomycosis who fail antifungal therapy



Dermatology 207(4): 375-380



Background: With the increased awareness of onychomycosis and the increasing use of antifungals for this indication, it is prudent to be concerned about the possible emergence of resistant strains. There has been substantial work on the development of standardized methods for testing the in vitro resistance of various fungi and yeasts to the currently available antifungal agents. However, relatively little research has been published concerning the resistance of dermatophyte species.

(PDF emailed within 0-6 h: $19.90)

Accession: 048996961

Download citation: RISBibTeXText

PMID: 14657630

DOI: 74118



Related references

Evaluation of improvement of onychomycosis in HIV-infected patients after initiation of combined antiretroviral therapy without antifungal treatment. Mycoses 58(9): 516-521, 2016

Evaluation of topical antifungal products in an in vitro onychomycosis model. Mycoses 59(5): 327-330, 2016

Development of a novel in vitro onychomycosis model for the evaluation of topical antifungal activity. Journal of Microbiological Methods 112: 73-75, 2015

Symptom improvement in patients with onychomycosis receiving oral antifungal therapy. Southern Medical Journal 95(11): 1359-1360, 2003

Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis. Antimicrobial Agents and ChemoTherapy 57(4): 1610-1616, 2013

In vitro evaluation of the acquisition of resistance, antifungal activity and synergism of Brazilian red propolis with antifungal drugs on Candida spp. Journal of Applied Microbiology 118(4): 839-850, 2016

Etiology of esophageal disease in human immunodeficiency virus-infected patients who fail antifungal therapy. American Journal of Medicine 101(6): 599-604, 1996

In vitro antifungal susceptibility of dermatophyte strains causing tinea pedis and onychomycosis in patients with non-insulin-dependent diabetes mellitus: a case-control study. Journal of the European Academy of Dermatology and Venereology 24(12): 1442-1446, 2011

Antifungal therapy for onychomycosis in children. Clinics in Dermatology 33(3): 333-339, 2016

Antifungal pulse therapy for onychomycosis. Journal of Family Practice 42(4): 348-348, 1996

Fifth toenail clinical response to systemic antifungal therapy is not a marker of successful therapy for other toenails with onychomycosis. Journal of the European Academy of Dermatology and Venereology 20(10): 1194-1196, 2006

Efficacy of antifungal PACT in an in vitro model of onychomycosis. Journal of the European Academy of Dermatology and Venereology 29(1): 86-90, 2015

Improvement of onychomycosis without antifungal therapy after initiation of highly active anti-retroviral therapy (HAART) in an HIV-infected patient. Japanese Journal of Infectious Diseases 52(6): 245-246, 1999

Improvement of onychomycosis without antifungal therapy after initiation of highly active anti-retroviral therapy (HAART) in an HIV-infected patient. Japanese Journal of Infectious Diseases 52(6): 245-246, 2000

"In vitro" antifungal activity of ozonized sunflower oil on yeasts from onychomycosis. Brazilian Journal of Microbiology 43(4): 1315-1318, 2013